Stemcyte, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 1997-01-01
- Employees
- 501
- Market Cap
- -
- Website
- http://www.stemcyte.com
Human Umbilical Cord Blood Infusion in Patients with Acute Ischemic Stroke (AIS)
Phase 2
Not yet recruiting
- Conditions
- Acute Ischemic Stroke
- Interventions
- Biological: hUCB
- First Posted Date
- 2023-09-15
- Last Posted Date
- 2025-02-27
- Lead Sponsor
- StemCyte, Inc.
- Target Recruit Count
- 39
- Registration Number
- NCT06040476
Human Umbilical Cord Blood (RegeneCyte) Infusion in Patients with Post-COVID Syndrome
Phase 2
Completed
- Conditions
- Post-COVID SyndromePost COVID-19 ConditionLong COVID
- Interventions
- Biological: Placebo
- First Posted Date
- 2023-01-12
- Last Posted Date
- 2025-03-24
- Lead Sponsor
- StemCyte, Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT05682560
- Locations
- 🇺🇸
Myrak Research Center, Miami Lakes, Florida, United States
Umbilical Cord Blood Cell (MC001) Transplant Into Injured Spinal Cord Followed by the Locomotor Training
Phase 2
Terminated
- Conditions
- Spinal Cord Injuries
- Interventions
- Biological: Umbilical Cord Blood Mononuclear CellOther: Locomotor Training
- First Posted Date
- 2019-06-07
- Last Posted Date
- 2025-02-28
- Lead Sponsor
- StemCyte, Inc.
- Target Recruit Count
- 6
- Registration Number
- NCT03979742
- Locations
- 🇨🇳
Hualien Tzu Chi Hospital, Hualien City, Taiwan
🇨🇳Taipei Medical University Hospital, Taipei City, Taiwan
© Copyright 2025. All Rights Reserved by MedPath